...
首页> 外文期刊>Placenta >Glyburide treatment in gestational diabetes is associated with increased placental glucose transporter 1 expression and higher birth weight
【24h】

Glyburide treatment in gestational diabetes is associated with increased placental glucose transporter 1 expression and higher birth weight

机译:妊娠期糖尿病中的糖甲脲处理与增加的胎盘葡萄糖转运蛋白1表达和较高的出生体重有关

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract Use of glyburide in gestational diabetes (GDM) has raised concerns about fetal and neonatal side effects, including increased birth weight. Placental nutrient transport is a key determinant of fetal growth, however the effect of glyburide on placental nutrient transporters is largely unknown. We hypothesized that glyburide treatment in GDM pregnancies is associated with increased expression of nutrient transporters in the syncytiotrophoblast plasma membranes. We collected placentas from GDM pregnancies who delivered at term and were treated with either diet modification (n?=?15) or glyburide (n?=?8). Syncytiotrophoblast microvillous (MVM) and basal (BM) plasma membranes were isolated and expression of glucose (glucose transporter 1; GLUT1), amino acid (sodium-coupled neutral amino acid transporter 2; SNAT2 and L-type amino acid transporter 1; LAT1) and fatty acid (fatty acid translocase; FAT/CD36, fatty acid transporter 2 and 4; FATP2, FATP4) transporters was determined by Western blot. Additionally, we determined GLUT1 expression by confocal microscopy in cultured primary human trophoblasts (PHT) after exposure to glyburide. Birth weight was higher in the glyburide-treated group as compared to diet-treated GDM women (3764?±?126?g vs . 3386?±?75?g; p ??0.05). GLUT1 expression was increased in both MVM (+50%; p ??0.01) and BM (+75%; p ??0.01). In contrast, MVM FAT/CD36 (?65%; p ?=?0.01) and FATP2 (?65%; p ?=?0.02) protein expression was reduced in mothers treated with glyburide. Glyburide increased membrane expression of GLUT1 in a dose-dependent manner in cultured PHT. This data is the first to show that glyburide increases GLUT1 expression in syncytiotrophoblast MVM and BM in GDM pregnancies, and may promote transplacental glucose delivery contributing to fetal overgrowth. Highlights ? Use of glyburide in GDM pregnancies has raised concerns about increased adverse neonatal side effects. ? The effect of glyburide on placental nutrient transporters is largely unknown. ? Glyburide increases syncytiotrophoblast GLUT1 expression in GDM pregnancies. ? Glyburide may promote transplacental glucose delivery, contributing to fetal overgrowth.
机译:摘要在妊娠期糖尿病(GDM)中的含量在胎儿和新生儿副作用中提出了担忧,包括增加出生体重。胎盘营养转运是胎儿生长的关键决定因素,但是亚溴脲对胎盘营养转运蛋白的影响在很大程度上是未知的。我们假设GDM妊娠中的甘氨酸治疗与同步性转发血浆膜中营养转运蛋白的表达增加有关。我们从术语交付的GDM怀孕中收集了胎盘,并用饮食修饰(n?= 15)或糖甲脲(n?=?8)治疗。分离单胞生殖微粒细胞(MVM)和基础(BM)血浆膜和葡萄糖(葡萄糖转运蛋白1; GLUT1),氨基酸(偶联中性氨基酸转运蛋白2; SNAT2和L型氨基酸转运蛋白1; LAT1)和脂肪酸(脂肪酸转象酶;脂肪/ CD36,脂肪酸转运蛋白2和4; FATP2,FATP4)转运蛋白由Western印迹测定。另外,我们在暴露于亚甲磺脲后通过共聚焦显微镜通过共聚焦显微镜测定Glut1表达。与饮食治疗的GDM女性相比,亚溴脲处理组的出生体重较高(3764?±126μm≤1386Ω·Δ75≤j≤≤0.05)。在MVM(+ 50%; P 1 50%; + 0.01)和BM(+ 75%;p≤01)中,GLUT1表达增加。相反,MVM脂肪/ CD36(α65%; p?= 0.01)和FATP2(α65%;p≤02)蛋白质表达,母体在用亚甲磺酸盐处理的母亲中降低。亚丙磺脲以培养的PHT在剂量依赖性方式增加了Glut1的膜表达。该数据是第一个显示甘氨酸在GDM妊娠中增加了Glut1表达的Glut1表达,并可促进胎儿过度生长的转脑葡萄糖输送。强调 ?在GDM怀孕中使用亚甲磺脲提出了对不良新生儿副作用的担忧。还糖甲酰脲对胎盘营养转运蛋白的影响主要是未知的。还亚甲磺脲增加了GDM妊娠中的同步性营养细胞增多。还亚甲磺脲可以促进转脑葡萄糖递送,促进胎儿过度生长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号